NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Ralph Niven, PhD

Ralph has over 25 years of broad experience in translational medicine with a specific emphasis on inhaled drug development. Ralph has driven the experimental and clinical development of small molecules and biomolecules employing a variety of delivery systems, at both startups and large pharmaceutical companies including Novartis, APT Pharmaceuticals, and Amgen.